에 대한 최신 뉴스 Dominari Holdings (NASDAQ:DOMH) 주식

Dominari Holdings

Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

$BTC

DOMH

LCID

MRNA

NVDA

TSLA

월요일(31일) 미국 증시는 위험 심리가 여전한 가운데 어려운 하루를 보냈다. S&amp;P 500 지수는 6개월 만에 최저치를 기록하는 등 변동성이 큰 장세를 보이다가 일부 손실을 회복했다. 주목받은 주식: 엔비디아, 모더나, 루시드, 도미나리 및 테슬라

월요일 주목받은 주식: 엔비디아, 모더나, 루시드, 도미나리 및 테슬라

Dominari Holdings Inc

Citigroup analyst Filippo Falorni maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Buy and lowers the price target from $200 to $181.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Procter & Gamble, Lowers Price Target to $181

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) has outperformed the market over the past 10 years by 21.51% on an annualized basis producing an average annual return of 31.61%. Currently, HubSpot has a market capitalization of $31.48 billion. 
Buying $100 In HUBS: If an investor had bought $100 of HUBS stock 10 years ago, it would be worth $1,527.60 today based on a price of $603.55 for HUBS at the time of writing.
<h3>HubSpot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745590517_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

HUBS

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) with a Buy and lowers the price target from $5.75 to $4.5.

VYNE

HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $4.5

Citigroup analyst Filippo Falorni maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $170 to $160.

Citigroup Maintains Buy on PepsiCo, Lowers Price Target to $160

Benchmark analyst David Williams maintains Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) with a Buy and lowers the price target from $170 to $160.

PLXS

Benchmark Maintains Buy on Plexus, Lowers Price Target to $160

Citigroup analyst Ygal Arounian maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Neutral and lowers the price target from $52 to $35.

Citigroup Maintains Neutral on Ziff Davis, Lowers Price Target to $35

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Friday.
Following the market opening Friday, the Dow traded down 0.50% to 39,894.22 while the NASDAQ fell 0.11% to 17,147.08. The S&amp;P 500 also fell, dropping, 0.24% to 5,471.83.
Check This Out: <a href="https://www.benzinga.com/25/04/45006599/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 0.9% on Friday.
In trading on Friday, health care fell by 0.9%.
Top Headline
Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported better-than-expected first-quarter financial results after the closing bell on Thursday.
Alphabet announced a 5% increase to the dividend with the quarterly payout going to 21 cents per share. The company also announced the Board of Directions authorized a $70 billion share repurchase plan on April 23.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares shot up 80% to $1.53. U.S. President Donald Trump signed an executive order Thursday to jumpstart the U.S. deep-sea mining industry. Trump seeks to secure domestic access to critical resources through this initiative and reduce America&#8217;s dependence on foreign supply chains for increasingly important commodities.</li>
<li>Shares of Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>)got a boost, surging 77% to $0.3288 as the company announced plans to invest tens of millions of dollars over next five years to establish new ecosystem for autism rehabilitation.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) shares were also up, gaining 47% to $0.0572.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Azul S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) shares dropped 45% to $0.6175.</li>
<li>Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) were down 33% to $8.35. Coeptis Therapeutics and Z Squared Inc. announced a merger agreement.</li>
<li>Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) was down, falling 23% to $1.28 as the company announced a $2 million registered direct offering of common stock.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $62.55 while gold traded down 1.7% at $3,293.10.
Silver traded down 2.1% to $32.805 on Friday, while copper fell 0.9% to $4.8120.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX 40 gained 0.8% and France's CAC 40 gained 0.7%. Spain's IBEX 35 Index gained 1.3%, while London's FTSE 100 rose 0.2%.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 surging 1.90%, China's Shanghai Composite falling 0.07%, Hong Kong's Hang Seng Index gaining 0.32% and India's BSE Sensex falling 0.74%.
Economics
U.S. consumer confidence declined to 52.20 points in April compared to 57 points in March.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006630/jim-cramer-onemain-is-too-risky-recommends-buying-reddit">Jim Cramer: OneMain Is &#8216;Too Risky,&#8217; Recommends Buying Reddit</a> </li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006630/jim-cramer-onemain-is-too-risky-recommends-buying-reddit">Jim Cramer: OneMain Is &#8216;Too Risky,&#8217; Recommends Buying Reddit</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

AGMH

AZUL

COEP

GOOG

GOOGL

LEXX

OMEX

Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results

Needham analyst Gerald Pascarelli reiterates Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Boston Beer Coto Hold

Citigroup analyst Ronald Josey maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and lowers the price target from $280 to $238.

Citigroup Maintains Buy on Wix.com, Lowers Price Target to $238

Citigroup analyst Ygal Arounian maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Neutral and raises the price target from $28 to $30.

Citigroup Maintains Neutral on Wayfair, Raises Price Target to $30

IONL

Trading Halt: Halt status updated at 10:06:28 AM ET: Quotation Resumption: News and Resumption Times

Seaport Global analyst Laurie Havener Hunsicker upgrades HarborOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) from Neutral to Buy and announces $16 price target.

Upgrades

HONE

Seaport Global Upgrades HarborOne Bancorp to Buy, Announces $16 Price Target

Citigroup analyst Ygal Arounian maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and lowers the price target from $70 to $63.

Citigroup Maintains Buy on Trade Desk, Lowers Price Target to $63

Citigroup analyst Ygal Arounian maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Neutral and lowers the price target from $5.9 to $4.

Citigroup Maintains Neutral on Outbrain, Lowers Price Target to $4

Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Revvity to report an earnings per share (EPS) of $0.96.
The announcement from Revvity is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Revvity's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.13</td>
<td>1.12</td>
<td>0.93</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.42</td>
<td>1.28</td>
<td>1.22</td>
<td>0.98</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589817_0.png" alt="eps graph" />
<h3>Market Performance of Revvity's Stock</h3>
Shares of Revvity were trading at $95.13 as of April 24. Over the last 52-week period, shares are down 11.01%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Revvity</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Revvity.
The consensus rating for Revvity is Outperform, based on 6 analyst ratings. With an average one-year price target of $128.17, there's a potential 34.73% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Avantor, Illumina and Tempus AI, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Avantor, with an average 1-year price target of $23.8, suggesting a potential 74.98% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Illumina, with an average 1-year price target of $129.4, suggesting a potential 36.02% upside.</li>
<li>Analysts currently favor an Buy trajectory for Tempus AI, with an average 1-year price target of $63.78, suggesting a potential 32.95% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Avantor, Illumina and Tempus AI, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>4.81%</td>
<td>$412.29M</td>
<td>1.21%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.10%</td>
<td>$562.90M</td>
<td>8.70%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-1.60%</td>
<td>$728M</td>
<td>8.31%</td>
</tr>
<tr>
<td>Tempus AI</td>
<td>Buy</td>
<td>35.85%</td>
<td>$122.06M</td>
<td>-23.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Revvity ranks first in revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
<h3>Unveiling the Story Behind Revvity</h3>
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
<h3>Understanding the Numbers: Revvity's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Revvity's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 4.81%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Revvity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.75%, the company showcases effective utilization of assets.
Debt Management: Revvity's debt-to-equity ratio is below the industry average. With a ratio of 0.43, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/RVTY/earnings">To track all earnings releases for Revvity visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RVTY

Earnings Preview For Revvity

Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Alexandria Real Estate will report an earnings per share (EPS) of $2.29.
Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 4.76% drop in the share price on the subsequent day.
Here's a look at Alexandria Real Estate's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.39</td>
<td>2.38</td>
<td>2.34</td>
<td>2.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.39</td>
<td>2.37</td>
<td>2.36</td>
<td>2.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589800_0.png" alt="eps graph" />
<h3>Tracking Alexandria Real Estate's Stock Performance</h3>
Shares of Alexandria Real Estate were trading at $77.26 as of April 24. Over the last 52-week period, shares are down 35.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Alexandria Real Estate</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.
A total of 2 analyst ratings have been received for Alexandria Real Estate, with the consensus rating being Neutral. The average one-year price target stands at $115.0, suggesting a potential 48.85% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Healthpeak Properties, Omega Healthcare Invts and Healthcare Realty Trust, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Healthpeak Properties, with an average 1-year price target of $23.75, suggesting a potential 69.26% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Omega Healthcare Invts, with an average 1-year price target of $39.67, suggesting a potential 48.65% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Healthcare Realty Trust, with an average 1-year price target of $16.5, suggesting a potential 78.64% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Healthpeak Properties, Omega Healthcare Invts and Healthcare Realty Trust are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>2.78%</td>
<td>$522.82M</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>26.07%</td>
<td>$420.96M</td>
<td>0.05%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>16.71%</td>
<td>$275.87M</td>
<td>2.59%</td>
</tr>
<tr>
<td>Healthcare Realty Trust</td>
<td>Neutral</td>
<td>-7.15%</td>
<td>$176.19M</td>
<td>-2.00%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Alexandria Real Estate ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, the company's performance is mixed compared to its peers, with strong revenue growth and gross profit but lower return on equity.
<h3>All You Need to Know About Alexandria Real Estate</h3>
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
<h3>Key Indicators: Alexandria Real Estate's Financial Health</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Alexandria Real Estate's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.78%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Alexandria Real Estate's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -8.51%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alexandria Real Estate's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.36%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alexandria Real Estate's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Alexandria Real Estate's debt-to-equity ratio is below the industry average. With a ratio of 0.71, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ARE/earnings">To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Alexandria Real Estate's Earnings Potential

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nucor to report an earnings per share (EPS) of $0.56.
Anticipation surrounds Nucor's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.59 in the last quarter, leading to a 3.76% increase in the share price on the following day.
Here's a look at Nucor's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.63</td>
<td>1.47</td>
<td>2.35</td>
<td>3.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.22</td>
<td>1.49</td>
<td>2.68</td>
<td>3.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589789_0.png" alt="eps graph" />
<h3>Performance of Nucor Shares</h3>
Shares of Nucor were trading at $115.29 as of April 24. Over the last 52-week period, shares are down 33.91%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Nucor</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Nucor.
Analysts have given Nucor a total of 8 ratings, with the consensus rating being Outperform. The average one-year price target is $153.88, indicating a potential 33.47% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and Carpenter Tech, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $145.0, suggesting a potential 25.77% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Reliance, with an average 1-year price target of $327.0, suggesting a potential 183.63% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Carpenter Tech, with an average 1-year price target of $237.5, suggesting a potential 106.0% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Steel Dynamics, Reliance and Carpenter Tech, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-8.17%</td>
<td>$626.83M</td>
<td>1.45%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>12.84%</td>
<td>$441.73M</td>
<td>2.45%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>11.45%</td>
<td>$886.10M</td>
<td>2.79%</td>
</tr>
<tr>
<td>Carpenter Tech</td>
<td>Outperform</td>
<td>8.44%</td>
<td>$177.50M</td>
<td>4.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nucor ranks at the top for Gross Profit and Return on Equity among its peers. It is at the bottom for Revenue Growth.
<h3>About Nucor</h3>
Nucor Corp manufactures steel and steel products. The company's reportable segments are steel mills, steel products, and raw materials. A majority of its revenue is derived from the steel mills segment, which is engaged in producing sheet steel (hot-rolled, cold-rolled, and galvanized), plate steel, structural steel (wide-flange beams, beam blanks, H-piling, and sheet piling), and bar steel products. Nucor manufactures steel principally from scrap steel and scrap steel substitutes using electric arc furnaces (EAFs) along with continuous casting and automated rolling mills. The steel mills segment sells its products mainly to steel service centers, fabricators, and manufacturers located in the United States, Canada, and Mexico.
<h3>Nucor's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Nucor's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -8.17%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.16%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nucor's ROE excels beyond industry benchmarks, reaching 1.45%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nucor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.86% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.34, Nucor adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/NUE/earnings">To track all earnings releases for Nucor visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nucor's Earnings: A Preview

Shin-Etsu Chemical (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SHECY#OTC">SHECY</a>) is looking for Q1 GAAP EPS of $0.20. sees sales of $4.000 billion vs $664.80 billion analyst estimate.

Guidance

SHECY

Shin-Etsu Chemical Sees Q1 2026 GAAP Earning per ADS $0.20; Sees Sales $4.000B.

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Brown &amp; Brown to report an earnings per share (EPS) of $1.28.
The announcement from Brown &amp; Brown is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.09, which was followed by a 2.61% drop in the share price the next day.
Here's a look at Brown &amp; Brown's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.77</td>
<td>0.87</td>
<td>0.88</td>
<td>1.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.91</td>
<td>0.93</td>
<td>1.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>5.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589776_0.png" alt="eps graph" />
<h3>Tracking Brown &amp; Brown's Stock Performance</h3>
Shares of Brown &amp; Brown were trading at $117.76 as of April 24. Over the last 52-week period, shares are up 37.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Brown &amp; Brown</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Brown &amp; Brown.
Brown &amp; Brown has received a total of 9 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $120.0, the consensus suggests a potential 1.9% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Willis Towers Watson, Baldwin Insurance and Abacus Global Management, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Willis Towers Watson, with an average 1-year price target of $363.75, suggesting a potential 208.89% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Baldwin Insurance, with an average 1-year price target of $41.0, suggesting a potential 65.18% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Abacus Global Management, with an average 1-year price target of $11.5, suggesting a potential 90.23% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Willis Towers Watson, Baldwin Insurance and Abacus Global Management are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown &amp; Brown</td>
<td>Neutral</td>
<td>12.04%</td>
<td>$506M</td>
<td>3.21%</td>
</tr>
<tr>
<td>Willis Towers Watson</td>
<td>Buy</td>
<td>4.15%</td>
<td>$1.67B</td>
<td>16.15%</td>
</tr>
<tr>
<td>Baldwin Insurance</td>
<td>Neutral</td>
<td>14.86%</td>
<td>$44.98M</td>
<td>-3.42%</td>
</tr>
<tr>
<td>Abacus Global Management</td>
<td>Outperform</td>
<td>40.16%</td>
<td>$29.49M</td>
<td>-5.35%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Brown &amp; Brown ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.
<h3>Discovering Brown &amp; Brown: A Closer Look</h3>
Brown &amp; Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The Company markets and sells insurance products and services, in the property, casualty, and employee benefits areas. It provides customers with non-investment insurance contracts, as well as other targeted, customized risk management products and services. It has four reportable segments; the Retail segment; the Programs segment; the Wholesale Brokerage segment and; the Services segment. It generates the majority of its revenue from the Retail segment which provides insurance products and services to commercial, public and quasi-public, and Others through automobile dealer services F&amp;I businesses. Its geographic area is U.S., U.K., the Republic of Ireland, Canada, and Others.
<h3>Brown &amp; Brown's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Brown &amp; Brown's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.04% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Brown &amp; Brown's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Brown &amp; Brown's ROE stands out, surpassing industry averages. With an impressive ROE of 3.21%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Brown &amp; Brown's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Brown &amp; Brown's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<a href="https://www.benzinga.com/quote/BRO/earnings">To track all earnings releases for Brown &amp; Brown visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Brown & Brown

SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is preparing to release its quarterly earnings on Monday, 2025-04-28. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect SBA Comms to report an earnings per share (EPS) of $2.32.
The market awaits SBA Comms's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.46, leading to a 2.97% increase in the share price on the subsequent day.
Here's a look at SBA Comms's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.07</td>
<td>2.27</td>
<td>2.07</td>
<td>1.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.61</td>
<td>2.40</td>
<td>1.51</td>
<td>1.42</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745589764_0.png" alt="eps graph" />
<h3>Tracking SBA Comms's Stock Performance</h3>
Shares of SBA Comms were trading at $222.84 as of April 24. Over the last 52-week period, shares are up 9.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SBAC/earnings">To track all earnings releases for SBA Comms visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBAC

Insights into SBA Comms's Upcoming Earnings

Press Releases

Dominari Holdings Inc. Strengthens Team with Appointment of Experienced Accounting Team

Donald Trump Jr. and Eric Trump Join Dominari Holdings Inc.'s Advisory Board

Dividends

Dominari Holdings Inc. Announces $13.5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules and Declares Special Cash Dividend

Dominari Announces Strategic Entry into U.S. AI Data Center Market

Power Metallic Mines Inc. (TSX.V: PNPN) Dominates TSX Venture Top 50: #1 Miner, #4 Overall – More Stocks Inside!

Dominari Securities Receives FINRA Approval to Expand Operations

Dominari Holdings Reports Preliminary FY 2024 Financial Results

Fintech

Contracts

Small Cap

Dominari Holdings Investment, American Data Centers, Becomes American Bitcoin in Transformative Bitcoin Mining Deal with Hut 8

authID Announces Pricing of Approximately $8,150,000 Million Registered Direct Offering

Dominari Holdings Highlights Supporting American Companies

AUID

DWAC

FMTO

IBIT

KAVL

PNPNF

TSXV:YGT

UMAC

WAFU

YGTFF

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

AtlasClear Holdings

Garden Stage

Lazard

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

PJT Partners

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

B. Riley Financial

Siebert Finl

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

UP Fintech Holding

TOP Financial Group Limited - Class A Ordinary Shares

TOP Finl Gr

Virtu Financial, Inc. - Class A Common Stock

Virtu Finl

Top KingWin Ltd - Class A Ordinary Shares

Top KingWin

Waton Financial Limited - Ordinary Shares

Waton Financial

월요일(31일) 미국 증시는 위험 심리가 여전한 가운데 어려운 하루를 보냈다. S&amp;P 500 지수는 6개월 만에 최저치를 기록하는 등 변동성이 큰 장세를 보이다가 일부 손실을 회복했다. S&amp;P는 0.5% 상승한 5,611.85포인트로 마감했다. 그럼에도 불구하고 지수는 2022년 9월 이후 최악의 한 달을 보내고 있으며 3월에는 7% 하락했다. 다우존스 산업평균지수는 1% 상승한 42,001.76포인트로 마감했다.
한편, 기술주들은 반도체 주가가 큰 폭으로 하락하면서 나스닥 100 지수는 0.14% 하락한 17,299.29포인트를 기록하는 등 어려움을 겪었다.
월요일에 소매 투자자와 트레이어들에게 주목을 받았던 주요 주식은 다음과 같다.
엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
월요일 엔비디아의 주가는 1.18% 하락하여 108.38달러로 마감했으며, 장중 최고가는 110.96달러, 최저가는 103.65달러였다. 주가의 52주 범위는 153.13~75.61달러 사이다. 엔비디아는 향후 4년간 미국 공급망에 수십억 달러를 투자할 계획을 발표했다. 젠슨 황 CEO는 <a href="//www.benzinga.com/25/03/44567096/nvidia-to-invest-billions-in-u-s-supply-chain-as-tech-companies-commit-to-trumps-onshoring-pledge"" target="_blank" rel="noopener">TSMC</a> 및 폭스콘과 같은 공급업체 덕분에 투자가 가능하다고 말했다.
모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
모더나 주가는 8.90% 하락한 28.35달러로 마감했다. 최고가 28.95달러, 최저가 26.80달러를 기록했고, 장중 52주 신저가를 기록했다. 이러한 하락은 미국 식품의약국(FDA)의 변동과 관련이 있다. <a href="https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on" target="_blank" rel="noopener">피터 마크스</a>가 FDA의 생물학적제제 평가 및 연구 센터에서 사임하면서 영향을 받았다.
루시드 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)
루시드의 주가는 4.31% 상승한 2.42달러로 최고가 2.44달러, 최저가 2.21달러를 기록했다. 52주 범위는 4.43달러에서 1.93달러다. 월요일 상승은 루시드의 경영진이 이전 테슬라 소유주의 주문이 "극적인 증가"를 <a href="https://in.benzinga.com/25/03/44570246/whats-going-on-with-lucid-stock-today" target="_blank" rel="noopener">언급하는 낙관적 발언 이후 나왔다.</a>
도미나리 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)
도미나리의 주가는 16.32% 하락한 4달러로 최고가 5.46달러, 최저가 3.84달러를 기록했다. 주가의 52주 범위는 13.58~0.83달러다. 이러한 하락은 헛 8(Hut 8 Corp)과 비트코인 <a href="https://in.benzinga.com/trading-ideas/movers/25/03/44566377/whats-going-on-with-dominari-holdings-stock-monday" target="_blank" rel="noopener">채굴 계약</a> 발표와 직접 공모 발표 이후 나왔다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 1.67% 하락한 259.16달러로 장중 최고가 260.56달러, 최저가 243.36달러를 기록했다. 52주 범위는 488.54~138.8달러다. 어려움에도 불구하고 일론 머스크는 현재 상황을 <a href="https://in.benzinga.com/25/03/44557947/doge-blowback-aside-elon-musk-considers-tesla-a-solid-opportunity" target="_blank" rel="noopener">매수 기회로 보고 있으며</a> 테슬라의 미래에 대해 낙관적인 태도를 유지하고 있다.
이미지 출처: Shutterstock
<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.
벤징가 엣지 주식 랭킹의 성장 부문에서 루시드는 백분위 97에 위치한다. 테슬라와의 비교가 궁금하다면 <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noopener">여기를 클릭해서 확인해 보자.</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" class="wp-image-850215" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png" sizes="(max-width: 695px) 100vw, 695px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png 695w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38-300x45.png 300w" alt="" width="695" height="105" /></a></figure>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.

Comments

Dominari Holdings

뉴스

에 대한 최신 뉴스 Dominari Holdings (NASDAQ:DOMH) 주식

화요일, 4월 01, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌